LAEKNA-B(02105),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02105 LAEKNA-B

Closed 03-18 16:08:11

13.520

+0.240

+1.81%

High13.780	Low12.900	Vol1.42M
Open12.900	D1 Closing13.280	Amplitude6.63%
Mkt Cap5.52B	Tradable Cap5.52B	Total Shares408.00M
T/O19.12M	T/O Rate0.35%	Tradable Shares408.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"LAEKNA-B","latestPrice":13.52,"timestamp":1742285291030,"preClose":13.28,"halted":0,"volume":1421500,"delay":0,"floatShares":408000000,"shares":408000000,"eps":-1.805415978353936,"marketStatus":"Closed","change":0.24,"latestTime":"03-18 16:08:11","open":12.9,"high":13.78,"low":12.9,"amount":19119920,"amplitude":0.066265,"askPrice":13.56,"askSize":500,"bidPrice":13.48,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-0.8915242570411867,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1742347800000},"marketStatusCode":5,"adr":0,"listingDate":1687968000000,"exchange":"SEHK","adjPreClose":13.28,"openAndCloseTimeList":[[1742261400000,1742270400000],[1742274000000,1742284800000]],"volumeRatio":0.335826,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105","defaultTab":"news","newsList":[{"id":"2505004866","title":"Laekna, Inc.'s (HKG:2105) market cap dropped HK$392m last week; individual investors who hold 36% were hit as were institutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2505004866","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505004866?lang=en_us&edition=full_marsco","pubTime":"2025-01-24 06:52","pubTimestamp":1737672758,"startTime":"0","endTime":"0","summary":"Key Insights Significant control over Laekna by private equity firms implies that the general public has more power to...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2105/laekna-shares/news/laekna-incs-hkg2105-market-cap-dropped-hk392m-last-week-indi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2503314182","title":"Laekna Successfully Completes Phase I Trial Of Obesity Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2503314182","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503314182?lang=en_us&edition=full_marsco","pubTime":"2025-01-13 09:50","pubTimestamp":1736733013,"startTime":"0","endTime":"0","summary":"Laekna  completed the phase I single ascending dose study  of LAE102 for treating obesity, according to a Monday filing with the Hong Kong bourse.Studies have been carried out in China and the US. LAE102 is a monoclonal antibody that specifically targets ActRIIA, a receptor involved in muscle regeneration and fat metabolism, the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"1158586609","title":"Stock Track | Laekna Plummets 5.08% as Phase I Trial Update Fails to Impress Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=1158586609","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158586609?lang=en_us&edition=full_marsco","pubTime":"2024-12-04 09:38","pubTimestamp":1733276302,"startTime":"0","endTime":"0","summary":"Laekna, a biotechnology company focused on developing innovative therapies, saw its stock price plummet 5.08% in Wednesday's intraday trading session. The decline comes despite the company's announcement regarding the progress of its phase I clinical trial for LAE102, a monoclonal antibody targeting ActRIIA.According to the company's filing with the Hong Kong stock exchange, the phase I trial is progressing effectively, with all 64 subjects across eight groups receiving intravenous and subcutane","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Laekna Plummets 5.08% as Phase I Trial Update Fails to Impress Investors","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02105"],"gpt_icon":0},{"id":"2488909456","title":"Laekna Doses All Subjects in LAE102 Phase I Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2488909456","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488909456?lang=en_us&edition=full_marsco","pubTime":"2024-12-04 08:24","pubTimestamp":1733271895,"startTime":"0","endTime":"0","summary":"Laekna  said the phase I clinical trial of LAE102 is progressing effectively, with all 64 subjects in eight groups receiving intravenous and subcutaneous injections of the single ascending dose study, according to a Wednesday filing with the Hong Kong bourse.LAE102 is a monoclonal antibody selectively targeting ActRIIA, a receptor essential in muscle regeneration and lipid metabolism, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2486399739","title":"Laekna Obesity Drug Begins Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2486399739","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486399739?lang=en_us&edition=full_marsco","pubTime":"2024-11-28 18:31","pubTimestamp":1732789883,"startTime":"0","endTime":"0","summary":"Laekna  advanced its obesity drug LAE123 to pre-clinical candidate declaration and has commenced an IND-enabling study of the drug for treating severe diseases, according to a Wednesday filing with the Hong Kong bourse.LAE123 is a strong ActRIIA and ActRIIB blocker with superior potency in cell-based reporter gene assays  aimed at finding cures for severe diseases, such as pulmonary arterial hypertension and spinal muscular atrophy.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RGA","BK1161","BK4019","02105"],"gpt_icon":0},{"id":"1171959242","title":"Stock Track | LAEKNA-B Soars 5.77% as Muscle Weakness Drug Study Commences","url":"https://stock-news.laohu8.com/highlight/detail?id=1171959242","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171959242?lang=en_us&edition=full_marsco","pubTime":"2024-11-28 10:14","pubTimestamp":1732760068,"startTime":"0","endTime":"0","summary":"Shares of LAEKNA-B, the biotech firm traded on the Hong Kong exchange, surged 5.77% in Thursday's intraday trading session. The stock's rally came after the company announced the commencement of an investigational new drug-enabling study for its muscle weakness treatment candidate LAE123.LAE123 is a novel drug that inhibits activin type II receptors ActRIIA/IIB, which play a key role in preventing sarcopenia or age-related muscle loss and weakness. By targeting these receptors, Laekna aims to de","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02105"],"gpt_icon":0},{"id":"2486339400","title":"Laekna Starts Investigational New Drug-Enabling Study for Muscle Weakness Pill","url":"https://stock-news.laohu8.com/highlight/detail?id=2486339400","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486339400?lang=en_us&edition=full_marsco","pubTime":"2024-11-28 10:09","pubTimestamp":1732759760,"startTime":"0","endTime":"0","summary":"Laekna  commenced its investigational new drug-enabling study for its LAE123 drug, according to a Thursday filing with the Hong Kong Exchange.LAE123 inhibits activin type II receptors or ActRIIA/IIB and helps prevent sarcopenia or muscle weakness.The company has advanced the drug to pre-clinical candidate declaration, the filing said.Price : $15.04, Change: $-0.22, Percent Change: -1.44%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HKD","BK4588","BK1161","BK4023","02105","BK4526","BK4585"],"gpt_icon":0},{"id":"2485487566","title":"BUZZ-China's Laekna falls most in 7 months on discounted share sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2485487566","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485487566?lang=en_us&edition=full_marsco","pubTime":"2024-11-21 12:30","pubTimestamp":1732163408,"startTime":"0","endTime":"0","summary":"** Shares of Chinese biotechnology firm Laekna    slump 14.9% to HK$13.38, on course for the biggest one-day pct drop since April 16    ** Stock third-biggest pct loser in Hang Seng Composite Index   , which slips 0.2%   ** Laekna plans to sell 17.64 mln new shares to raise HK$235.6 mln  for accelerating research and development of obesity drug LAE102 and other drug assets   ** New shares will be issued at HK$13.36 each, a 15.01% discount to Wednesday's close of HK$15.72 per share   ** Stock soared 48% on Wednesday after it entered into agreement with Eli Lilly    to develop an experimental obesity drug LAE102 to help patients lose weight while preserving muscle    ** Hang Seng Commerce & Industry Index    climbs 0.1%, healthcare index    adds 0.03%, while Hang Seng Index  slips 0.1%   ** Laekna shares down 29.4% YTD    ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1551013342.USD","SG9999015952.SGD","LU0094547139.USD","LU0061475181.USD","LU0203202063.USD","LU0882574139.USD","SG9999017495.SGD","LU2602419157.SGD","LU2264538146.SGD","SG9999014898.SGD","LU0943347566.SGD","SG9999013999.USD","LU2112291526.USD","IE00BK4W5L77.USD","BK4585","LU0238689110.USD","LU0354030511.USD","LU1868836914.USD","BK1161","LU0109391861.USD","IE0009355771.USD","LU1093756325.SGD","LU0385154629.USD","SGXZ51526630.SGD","LU2324357040.USD","BK4007","LU2237443382.USD","LU0689472784.USD","LU2360106947.USD","LU0079474960.USD","LU0114720955.EUR","LU0471298777.SGD","LLY","LU1551013425.SGD","BK4516","LU1988902786.USD","LU2106854487.HKD","GB00BDT5M118.USD","LU1983299246.USD","LU1061106388.HKD","LU1712237335.SGD","SG9999018865.SGD","IE00B2B36J28.USD","LU0471298694.HKD","02105","LU2237443465.HKD","LU2491049909.HKD","LU1974910355.USD","LU1057294990.SGD","BK4533"],"gpt_icon":1},{"id":"2485483748","title":"Laekna Seeks HK$230 Million in Placement Deal; Shares Fall 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485483748","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485483748?lang=en_us&edition=full_marsco","pubTime":"2024-11-21 10:34","pubTimestamp":1732156447,"startTime":"0","endTime":"0","summary":"Laekna  will sell 17,636,000 new shares to at least six investors under a placing deal, according to a Thursday filing with the Hong Kong Exchange.The biotechnology company will shell the shares at HK$13.36 apiece.The shares represent 4.33% of Laekna's issued share capital, as enlarged by the placement.Net proceeds, estimated at HK$230.3 million, will be used to speed up research for the company's LAE102 weight-loss drug, the filing stated.Shares slid 9% during Thursday's morning trading.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"1116383768","title":"Stock Track | Laekna's Shares Plummet 10.94% on Plan to Place 17.6 Million New Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1116383768","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116383768?lang=en_us&edition=full_marsco","pubTime":"2024-11-21 09:30","pubTimestamp":1732152644,"startTime":"0","endTime":"0","summary":"Laekna's stock  plummeted by 10.94% during Thursday's trading session, underperforming the broader market.The sharp decline came after the company announced plans to place an aggregate of 17.6 million new shares at HK$13.36 per share. This share placement could dilute existing shareholders' stakes and weigh on the stock price.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Laekna's Shares Plummet 10.94% on Plan to Place 17.6 Million New Shares","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02105"],"gpt_icon":0},{"id":"2485105086","title":"BRIEF-Laekna To Place Aggregate 17.6 MLN Shares At Hk$13.36 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2485105086","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485105086?lang=en_us&edition=full_marsco","pubTime":"2024-11-21 08:17","pubTimestamp":1732148243,"startTime":"0","endTime":"0","summary":"BRIEF-Laekna To Place Aggregate 17.6 MLN Shares At Hk$13.36 Per ShareNov 21 (Reuters) - Laekna 2105.HK:PLACING OF NEW SHARESTO PLACE AGGREGATE 17.6 MILLION SHARES AT HK$13.36 PER PLACING SHAREFurther company coverage: 2105.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MR1BX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2485510516","title":"Laekna Inc - Placing of New Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2485510516","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485510516?lang=en_us&edition=full_marsco","pubTime":"2024-11-21 08:14","pubTimestamp":1732148042,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nFWN3MR1BX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2484148710","title":"China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2484148710","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484148710?lang=en_us&edition=full_marsco","pubTime":"2024-11-20 23:07","pubTimestamp":1732115266,"startTime":"0","endTime":"0","summary":"China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug Nov 20 (Reuters) - Eli Lilly LLY.N and Hong Kong-listed Laekna 2105.HK will collaborate to develop an experimen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nL4N3MR128:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1551013425.SGD","LU1366192091.USD","LU0256863811.USD","LU0385154629.USD","LU0097036916.USD","LU1868836914.USD","LU2063271972.USD","02105","LU1868837136.USD","LU2237443382.USD","LU0882574055.USD","LU1712237335.SGD","SGXZ31699556.SGD","LU0198837287.USD","SRRK","LU1061106388.HKD","LU2265009873.SGD","IE0004445239.USD","IE00B2B36J28.USD","LU0106261372.USD","SGXZ81514606.USD","SG9999015986.USD","LU1267930730.SGD","LU0061475181.USD","IE00BK4W5M84.HKD","LU0417517546.SGD","LU1035775433.USD","BK4588","LU2360106947.USD","LU1064131342.USD","LU0640476718.USD","SG9999001176.USD","SGXZ99366536.SGD","SG9999014898.SGD","LU2362541513.USD","LU0238689110.USD","LU2112291526.USD","LLY","LU0109394709.USD","LU1023059063.AUD","LU2237443895.HKD","SG9999001176.SGD","LU1814569148.SGD","REGN","LU1917777945.USD","LU2361044865.SGD","LU2491050154.USD","LU0466842654.USD","LU0079474960.USD"],"gpt_icon":1},{"id":"2484148831","title":"Laekna Inc - Lilly to Fund and Share Resources for Lae102 Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2484148831","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484148831?lang=en_us&edition=full_marsco","pubTime":"2024-11-20 22:00","pubTimestamp":1732111227,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUA8JSTS0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0238689110.USD","SGXZ31699556.SGD","LU0109391861.USD","LU0689472784.USD","LU1917777945.USD","IE00B1BXHZ80.USD","LU2237438978.USD","LU0708995401.HKD","LLY","LU0943347566.SGD","LU2461242641.AUD","SGXZ99366536.SGD","LU2491050154.USD","LU1093756325.SGD","LU2023250504.SGD","SG9999014880.SGD","BK4581","LU2237443382.USD","IE00BJT1NW94.SGD","LU1868837136.USD","SG9999015952.SGD","SG9999001176.SGD","LU1712237335.SGD","LU0096364046.USD","SG9999014906.USD","LU1064131342.USD","LU0471298694.HKD","SG9999017495.SGD","LU1061106388.HKD","BK1161","LU2360106947.USD","LU1623119135.USD","LU2602419157.SGD","SG9999018857.SGD","LU2089984988.USD","LU0006306889.USD","LU1804176565.USD","LU1280957306.USD","LU0203201768.USD","LU2264538146.SGD","LU0640476718.USD","LU2211815571.USD","LU2468319806.SGD","IE00BK4W5L77.USD","LU1023059063.AUD","IE0009355771.USD","LU1868836757.USD","LU2361044865.SGD","IE00BJLML261.HKD","02105"],"gpt_icon":0},{"id":"2484110931","title":"Laekna Announces a Clinical Collaboration With Lilly to Develop Lae102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2a for the Treatment of Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2484110931","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484110931?lang=en_us&edition=full_marsco","pubTime":"2024-11-20 22:00","pubTimestamp":1732111227,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUA8JSTS0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2484110071","title":"Laekna Inc - Retains Global Rights for Lae102","url":"https://stock-news.laohu8.com/highlight/detail?id=2484110071","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484110071?lang=en_us&edition=full_marsco","pubTime":"2024-11-20 22:00","pubTimestamp":1732111227,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUA8JSTS0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0096364046.USD","LU2089984988.USD","LU0006306889.USD","LU1868837136.USD","LU0689472784.USD","LU1868836757.USD","LU1623119135.USD","02105","LU2461242641.AUD","LU2360106947.USD","LU0471298694.HKD","SG9999001176.SGD","BK4581","LU0203201768.USD","LU1712237335.SGD","SG9999018857.SGD","LU2237438978.USD","IE00B1BXHZ80.USD","LU1280957306.USD","SGXZ31699556.SGD","LLY","LU2468319806.SGD","LU2023250504.SGD","LU2211815571.USD","LU0109391861.USD","IE0009355771.USD","SGXZ99366536.SGD","LU1064131342.USD","LU0708995401.HKD","BK1161","IE00BJLML261.HKD","LU1917777945.USD","SG9999014906.USD","LU0238689110.USD","LU0943347566.SGD","IE00BJT1NW94.SGD","SG9999017495.SGD","LU0640476718.USD","IE00BK4W5L77.USD","LU2264538146.SGD","LU2237443382.USD","LU1023059063.AUD","LU2602419157.SGD","LU1061106388.HKD","LU1804176565.USD","LU1093756325.SGD","LU2491050154.USD","SG9999014880.SGD","SG9999015952.SGD","LU2361044865.SGD"],"gpt_icon":0},{"id":"2484116259","title":"US-Based Eli  Lilly to Fund US Phase 1 Study for Laekna's Weight Loss Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2484116259","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484116259?lang=en_us&edition=full_marsco","pubTime":"2024-11-20 17:29","pubTimestamp":1732094949,"startTime":"0","endTime":"0","summary":"US-based drug company Eli Lilly will finance a phase 1 study in the US for Laekna's  LAE102 anti-obesity drug, according to a Wednesday filing with the Hong Kong Exchange.The drug helps target the ActRIIA receptor that helps with muscle regeneration and lipid metabolism, the filing said.Preclinical trials showed the drug helps boost muscular mass and decreases fat, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"1164337974","title":"Stock Track | LAEKNA-B Soars 43% on Obesity Drug Deal With Eli Lilly","url":"https://stock-news.laohu8.com/highlight/detail?id=1164337974","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164337974?lang=en_us&edition=full_marsco","pubTime":"2024-11-20 16:01","pubTimestamp":1732089680,"startTime":"0","endTime":"0","summary":"Shares of Hong Kong-listed biotech company Laekna Inc  skyrocketed 43.21% on Wednesday, surging to a 10-month high amid significant investor enthusiasm over the company's announced clinical collaboration with pharmaceutical giant Eli Lilly .Under the agreement, Eli Lilly will fund and execute a Phase 1 study of Laekna's experimental obesity treatment LAE102 in the United States. Notably, Laekna retains global rights to the drug, suggesting investors believe this deal could accelerate LAE102's de","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | LAEKNA-B Soars 43% on Obesity Drug Deal With Eli Lilly","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02105"],"gpt_icon":1},{"id":"2484156363","title":"BRIEF-Laekna Inc Announces Clinical Collaboration With Lilly","url":"https://stock-news.laohu8.com/highlight/detail?id=2484156363","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484156363?lang=en_us&edition=full_marsco","pubTime":"2024-11-20 14:03","pubTimestamp":1732082585,"startTime":"0","endTime":"0","summary":"BRIEF-Laekna Inc Announces Clinical Collaboration With LillyNov 20 (Reuters) - Laekna Inc 2105.HK:CLINICAL COLLABORATION WITH LILLY ON LAE102 IN U.S. FOR TREATMENT OF OBESITYFurther company coverage: 2105.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nFWN3MQ0YW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1280957306.USD","IE00BJJMRZ35.SGD","LU1551013425.SGD","LU2106854487.HKD","BK4585","LU1366192091.USD","LU0256863811.USD","LU1127390331.HKD","LU1868836914.USD","LU2264538146.SGD","02105","LU1804176565.USD","LU0122379950.USD","LU1551013342.USD","LU1061106388.HKD","LU2461242641.AUD","SG9999014906.USD","IE0004445239.USD","IE00B2B36J28.USD","LU0106261372.USD","LU0058720904.USD","SGXZ81514606.USD","LU0094547139.USD","SG9999015986.USD","LU0354030438.USD","LU0203201768.USD","LU0417517546.SGD","LU2360106947.USD","IE00BJT1NW94.SGD","LU2237443978.SGD","LU1064131342.USD","LU2237443549.SGD","LU2491050071.SGD","LU0823416689.USD","SGXZ99366536.SGD","LU0006306889.USD","LU1069344957.HKD","LU1868836591.USD","IE00BK4W5L77.USD","LU2112291526.USD","LU2324357040.USD","LLY","IE00BJLML261.HKD","LU2237438978.USD","LU2237443895.HKD","SG9999001176.SGD","LU0820561909.HKD","LU1917777945.USD","SGXZ51526630.SGD","SG9999018865.SGD"],"gpt_icon":0},{"id":"2484155241","title":"BUZZ-HK-listed Laekna hits 10-month peak on Eli Lilly deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2484155241","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484155241?lang=en_us&edition=full_marsco","pubTime":"2024-11-20 13:57","pubTimestamp":1732082220,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed Laekna hits 10-month peak on Eli Lilly deal** HK-listed shares of Laekna 2105.HK soar 37.2% to HK$14.54, highest since Jan. 11** Stock set for biggest one-day pct rise since April 15** Chinese biotech firm enters into agreement with Eli Lilly LLY.N to accelerate global clinical development of LAE102, used to treat obesity** Under the deal, Lilly will fund and execute LAE102's phase I study in the U.S., while Laekna will retain the drug's global rights** Hong Kong's healthcare index .HSCIH up 2.8%, while Hang Seng Index .HSI slips 0.1%** Stock trims YTD losses to 32.3%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nL1N3MR054:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868837136.USD","LU0109391861.USD","SG9999015952.SGD","LU0689472784.USD","LU0820561818.USD","LU2324357040.USD","LU2106854487.HKD","LU0882574055.USD","LU1551013342.USD","BK4588","SG9999014906.USD","LU2491050071.SGD","IE00B1BXHZ80.USD","SG9999018857.SGD","LU0471298694.HKD","LLY","LU0061475181.USD","LU1868836591.USD","GB00BDT5M118.USD","LU1868837300.USD","LU0203201768.USD","LU2237443549.SGD","LU2264538146.SGD","IE00B4R5TH58.HKD","LU1868836914.USD","LU0238689110.USD","BK1161","SGXZ31699556.SGD","IE00BFTCPJ56.SGD","BK4534","LU1868836757.USD","LU0203202063.USD","LU0823416689.USD","LU1093756325.SGD","IE0004445239.USD","LU0471298777.SGD","LU0385154629.USD","LU1988902786.USD","LU2468319806.SGD","SGXZ99366536.SGD","SG9999015978.USD","LU2265009873.SGD","SGXZ57979304.SGD","BK4533","IE00BK4W5L77.USD","LU0096364046.USD","LU0256863902.USD","LU0106261372.USD","LU1804176565.USD","02105"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":0.0457},{"period":"1month","weight":0.4674},{"period":"3month","weight":0.2868},{"period":"6month","weight":2.0251},{"period":"1year","weight":0.8117},{"period":"ytd","weight":0.4173}],"compareEarnings":[{"period":"1week","weight":0.0152},{"period":"1month","weight":0.0674},{"period":"3month","weight":0.2256},{"period":"6month","weight":0.3672},{"period":"1year","weight":0.444},{"period":"ytd","weight":0.2037}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer, liver diseases and obesity. The Company is still in the research and development stage. The Company's pipeline products include Afuresertib (LAE002), LAE001, LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, LAE102, LAE103, LAE104, LAE105, LAE106, LAE120, LAE123, and others. The Afuresertib is an adenosine triphosphate (ATP) competitive AKT inhibitor. The LAE001 is an androgen synthesis inhibitor that can inhibit CYP17A1 and CYP11B2 at the same time. The Company mainly conducts business in the Chinese, America, European, Korean, and other markets.","exchange":"SEHK","name":"LAEKNA-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.31.7","shortVersion":"4.31.7","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LAEKNA-B(02105),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LAEKNA-B(02105) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LAEKNA-B,02105,LAEKNA-B股票,LAEKNA-B股票老虎,LAEKNA-B股票老虎国际,LAEKNA-B行情,LAEKNA-B股票行情,LAEKNA-B股价,LAEKNA-B股市,LAEKNA-B股票价格,LAEKNA-B股票交易,LAEKNA-B股票购买,LAEKNA-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LAEKNA-B(02105),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LAEKNA-B(02105) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}